# US 2014/0154691 A1 · Methods and Compositions for the Treatment and Diagnosis of Bladder Cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154691 A1
- Document ID: US20140154691A1
- Status: Published application
- Kind: A1
- Application number: 14/127,895
- Filed: 2012-06-22
- Published: 2014-06-05
- Earliest claimed: 2011-06-22
- Assignees: Oncocyte Corporation
- Inventors: Karen Chapman; Joseph Wagner; Michael West; Markus Daniel Lacher; Jennifer Lorie Kidd
- Web page: https://patentgrep.com/patent/US20140154691A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- C12Q 2600/158: Expression markers
- G01N 2800/60: Complex ways of combining multiple protein biomarkers for diagnosis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Embodiments of the disclosure are directed to methods of diagnosis, prognosis and treatment of cancer. The methods are particularly suited for bladder cancer. The methods include targeting a marker that is expressed at abnormal levels in bladder cancer tissue in comparison to normal somatic tissue. Also disclosed are methods of treating cancer comprising administering a composition including a therapeutic that affects the expression or function of a target marker.

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A kit comprising a plurality of agents that bind to a plurality of markers chosen from COL10A1, FCRLB, AIM2, KRT6A, and MMP11.

### Claim 15 (depends on 14)

The kit of claim 14 comprising a plurality of agents that binds to each of the following markers COL10A1, FCRLB, AIM2, KRT6A, and MMP11.

### Claim 16 (depends on 14)

The kit of claim 14, wherein the plurality of agents are proteins and/or peptides.

### Claim 17 (depends on 16)

The kit of claim 16, wherein the proteins are antibodies and/or antibody fragments.

### Claim 18 (depends on 14)

The kit of claim 14, wherein the plurality of agents binds to COL10 and AIM2.

### Claim 19 (depends on 14)

The kit of claim 14, wherein the plurality of agents are nucleic acid oligonucleotides.

### Claim 20 (depends on 19)

The kit of claim 19, wherein the nucleic acid oligonucleotides are DNA oligonucleotides.

### Claim 21 (depends on 19)

The kit of claim 19, wherein the nucleic acid oligonucleotides bind to a DNA sequence encoding a plurality of markers chosen from COL10A1, FCRLB, AIM2, KRT6A, and MMP11.

### Claim 22 (depends on 15)

The kit of claim 15, wherein the plurality of agents are proteins and/or peptides.

### Claim 23 (depends on 22)

The kit of claim 22, wherein the proteins are antibodies and/or antibody fragments.

### Claim 24 (depends on 15)

The kit of claim 15, wherein the plurality of agents are nucleic acid oligonucleotides.

### Claim 25 (depends on 24)

The kit of claim 24, wherein the nucleic acid oligonucleotides are DNA oligonucleotides.

### Claim 26 (depends on 24)

The kit of claim 24, wherein the nucleic acid oligonucleotides bind to a DNA sequence encoding a plurality of markers chosen from COL10A1, FCRLB, AIM2, KRT6A, and MMP11.

### Claim 27 (depends on 14)

The use of the kit of claim 14 to detect bladder cancer.

### Claim 28 (depends on 15)

The use of the kit of claim 15 to detect bladder cancer.